Annovis Bio Announces Positive Phase Two Efficacy Data for Treatment of Parkinson’s Disease
Data Shows Statistically Significant Improvements in Speed and Motor Function in PD Patients
Annovis Bio to Request Meeting with FDA on Next Steps in Clinical Development
Investor Conference Call to be Hosted Tuesday, October 5th, 2021, at 9:00 am ET